Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.

[1]  C. Gridelli,et al.  Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. , 2001, Lung cancer.

[2]  M. Kris,et al.  Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: An international update. , 2001, Seminars in oncology.

[3]  V. Georgoulias,et al.  Phase I study of weekly Docetaxel (D) and Gemcitabine (G) in advanced non-small cell lung cancer , 2000 .

[4]  R. Lilenbaum,et al.  Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC) , 2000 .

[5]  R. Loddenkemper,et al.  Second line weekly docetaxel in advanced non small cell lung cancer , 2000 .

[6]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma , 2000, Cancer.

[7]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[8]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Roszkowski,et al.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). , 2000, Lung cancer.

[10]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[11]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Shepherd,et al.  Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. , 1997, Seminars in oncology.

[13]  A. Rossi,et al.  Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. , 1997, European journal of cancer.

[14]  S. Monfardini.  What do we know on variables influencing clinical decision-making in elderly cancer patients? , 1996, European journal of cancer.

[15]  D. Serraino,et al.  Lung cancer in the elderly. , 1997, Cancer treatment reviews.

[16]  R. Havlik,et al.  The national institute on aging and the national cancer institute seer collaborative study on comorbidity and early diagnosis of cancer in the elderly , 1994, Cancer.

[17]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.